Home・Stock List・Innoviva Inc

Innoviva Inc

Closed

SectorHealthcare

20.64 -0.15

Buy Sell

Overview

Share price change

24h

Current

Min

20.5

Max

20.84

Key metrics
By Trading Economics
Income	-270M -83M
Sales	22M 120M
P/E Sector Avg	4.754 57.002
EPS	0.59
Profit margin	-69.754
Employees	159
EBITDA	28M 267M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+96.66% upside

Dividends
By Acuity
Next Earnings	3 Nov 2026

Market Stats
By TradingEconomics
Market Cap	-39M 1.5B
Previous open	20.79
Previous close	20.64

News Sentiment

By Acuity

100%

324 / 340 Healthcare

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Aug 2026, 19:16 UTC

Innoviva Inc's shares are higher in Tuesday's session, reflecting a modest gain since Monday's close. The stock remains below its 20-day moving average.

10 Aug 2026, 19:16 UTC

News

Innoviva shares are higher despite mixed analyst ratings and a price target cut from Cantor Fitzgerald to $34.00. HC Wainwright maintains a $46.00 target.

7 Aug 2026, 21:01 UTC

Innoviva Inc shares are lower in after-market hours, reflecting a decline since Friday's close and trading near the lower end of their one-month range.

6 Aug 2026, 19:51 UTC

News

Innoviva Inc shares are higher as the company shifts to a diversified healthcare model, supported by $773 million in investments and positive momentum since Wednesday.

5 Aug 2026, 21:01 UTC

Innoviva Inc shares are trading higher in after-market hours, recovering from a session low. No specific news was identified to explain the movement.

3 Aug 2026, 19:46 UTC

News

Innoviva Inc shares are lower today, continuing a downward trend. Analysts from BTIG and HC Wainwright maintain buy ratings with targets of $42.00 and $46.00.

31 Jul 2026, 20:06 UTC

Shares of Innoviva Inc. are trading lower, continuing a downward trend. The stock remains below its 20-day moving average amid no specific news.

30 Jul 2026, 19:02 UTC

Innoviva Inc shares are declining amid market weakness and rising jobless claims. The stock remains near the lower end of its one-month range.

29 Jul 2026, 19:06 UTC

Macro Event

Innoviva Inc shares are lower today as market scrutiny increases following the Federal Reserve's decision to maintain interest rates amid ongoing geopolitical tensions.

28 Jul 2026, 20:03 UTC

Innoviva Inc shares are higher today, continuing an upward trend since Monday. No specific news was identified to explain the price movement.

27 Jul 2026, 19:56 UTC

Innoviva Inc shares are lower today, reflecting broader market trends amid a significant drop in oil prices. No specific company news was identified.

21 Jul 2026, 15:46 UTC

Innoviva Inc shares are higher today, reflecting a broader trend in rising equity indices. The stock remains below its 20-day moving average.

20 Jul 2026, 18:31 UTC

Innoviva Inc shares are lower today, reflecting broader weakness in the Pharmaceuticals sub-sector. The stock has reversed from a recent trend of higher closes.

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

96.66% upside

12 Months Forecast

Average 40.67 USD 96.66%

High 46 USD

Low 34 USD

Based on 3 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Innoviva Inc - Dist in the past 3 months.

Sentiment

By Acuity

324 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.